Recently, ArriVent announced that the global phase III FURVENT trial of vormetinib in collaboration with Iris has not reached the main research end. This trial targets first-line treatment of EGFR20 exon insertion mutation, locally advanced, or metastatic non-squamous non-small cell lung cancer. According to Tianyan Research, the 2026 semi-annual report of Shanghai Alice Pharmaceutical Technology Co., Ltd. revealed that as of June 30, the book value of ArriVent shares held by the company was about 302 million yuan, an increase of 67.31% over the end of the previous year. The report attributed the value-added value to the rise in ArriVent's stock price. The two sides also have another pharmaceutical cooperation: in August of this year, Alice obtained an exclusive license from Arrivent for R&D, production, registration and commercialization of the ADC drug AST12608 in China.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.